Litcius/Paper detail

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.

Makoto Nishio, Fabrice Barlési, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, G. Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski

2020Journal of Thoracic Oncology11 citations

Topics & Concepts

MedicineAtezolizumabOncologyChemotherapyInternal medicineLung cancerRandomized controlled trialCancerImmunotherapyPembrolizumabLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. | Litcius